glp 1 agonists and pancreatitis Reconciling GLP-1s Pancreatitis risk from GLP1 use

Encouragingly, GLP1R/GIPR agonists have demonstrated favorable outcomes in T2DM when studied in human clinical trials

Ludvik B, Giorgino F, Jodar E, Frias JP, Fernandez Lando L, Brown K, et al

Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)

13 In this review, we summarise the evidence related to the effects of GLP-1 RAs on these outcomes ( Figure 1 ), which may shed light on the potential of these agents to be used in the clinical care of HF patients and investigated in large clinical trials to evaluate clinical outcomes